P021 (Peptide 021) — what it does, evidence, and safety

What it is

P021 is a small, lab-designed peptide studied for brain protection and memory support in Alzheimer's research. In animal studies, it boosts the growth of new neurons, supports synapses, and reduces the abnormal tau buildup seen in Alzheimer's disease. It's derived from a natural nerve-growth protein called CNTF and was engineered to be stable enough to survive digestion, so it can be taken as a pill and still reach the brain. All of this evidence is in mice and rats, with no human trials, and it is not FDA-approved for any use.

What the research found

P021 has been studied for Alzheimer's disease and cognition, and its evidence is entirely preclinical. Derived from a nerve-growth factor and modified for oral, brain-penetrant dosing, it reduced abnormal tau, modestly lowered amyloid-beta, and rescued neurogenesis, synaptic markers, and memory in an Alzheimer's mouse model, and reduced age-related memory decline in aged rats. Not every result was positive: in a 2024 study by an independent group it helped neurons in culture but, given long-term to mice modeling CDKL5 deficiency disorder, failed to raise BDNF and did not correct brain-structure problems. No human studies have been published.

Status and regulatory position

Not FDA-approved for any indication. Investigational; evidence is entirely preclinical (mouse and rat models) — there are no human trials of P021. WADA status: not specifically named on the Prohibited List; as a non-approved research peptide it is best treated as captured under S0 (non-approved substances), prohibited at all times in regulated sport — verify with your anti-doping organization. Not DEA-scheduled.

Safety

P021 has no human safety data of any kind — all studies are in animals. It is not FDA-approved. As a non-approved research peptide it is best treated as prohibited in regulated sport at all times under the WADA S0 category; verify with your anti-doping organization. Because it promotes cell growth in the brain, unknown long-term effects are a reasonable concern. VialWise is a research and educational reference, not medical advice.

Disclosures

⚠️ For research and educational purposes only. P021 is not approved by the FDA for any indication. Its entire evidence base is preclinical (mice and rats) — there are no human trials. Information here is informational, not medical advice. Always confirm any dose calculation with the in-app calculator and consult appropriate professional guidance.

⚠️ All evidence is animal-model or cell-culture data. Every efficacy finding below comes from mouse, rat, or in-vitro studies, most from the research group that originated the compound.[¹][²][³][⁴] Encouraging preclinical results in neuroscience frequently fail to translate to humans — and P021 already has one published example of that gap: in an independent 2024 study, it worked in cultured neurons but did not improve BDNF or brain structure in live Cdkl5-knockout mice.[⁵] There is no human dose, no human safety data, and no human efficacy data for P021.

⚠️ Not specifically WADA-listed, but treat as S0. P021 is not named on the WADA Prohibited List, but as a non-approved research peptide it is best regarded as captured under S0 (non-approved substances), prohibited at all times in regulated sport. Verify with your anti-doping organization.

Quick reference

Compound class	A ciliary neurotrophic factor (CNTF)-derived tetrapeptide mimetic (Ac-DGGL(A)G-NH2), engineered with an adamantylated glycine to improve stability and blood-brain-barrier penetration. Neurogenic and neurotrophic in animal models.[¹][⁴]
Common vial sizes	Research-supply lyophilized vials, commonly ~. No FDA-approved product exists.
Frequency	Preclinical dosing was continuous (in-diet, daily). No established human regimen.
Half-life	Designed for improved metabolic stability versus native CNTF; specific human PK is not established. (Estimated / preclinical only.)
Route	Oral in the published studies (a deliberate design goal); research-community use is often subcutaneous. No approved route.[¹][²]
Onset of action	Preclinical effects were measured over weeks to months of continuous dosing.[²][³][⁴] No validated human effect exists.

In depth

P021 (also written Peptide 021) is a small peptide derived from ciliary neurotrophic factor (CNTF), a natural protein that supports the survival and growth of neurons. Full-length neurotrophic factors like CNTF and BDNF are attractive for neurodegenerative disease but are hard to use as drugs — they don't cross the blood-brain barrier well, have short half-lives, and can cause serious side effects. P021 was designed to overcome this: researchers used epitope mapping to identify CNTF's most active region, reduced it to a tetrapeptide, and added an adamantylated glycine to its C-terminus to slow enzymatic degradation and improve blood-brain-barrier penetration, making it stable and brain-penetrant enough for oral dosing.[¹][⁴]

Mechanism (as described in preclinical work). P021 is reported to be neurogenic and neurotrophic: it enhances dentate gyrus neurogenesis (the birth of new neurons in the hippocampus) and memory processes by inhibiting the LIF (leukemia inhibitory factor) signaling pathway and increasing BDNF expression. The increased BDNF is linked to reduced GSK-3β activity (a major tau kinase), which in turn reduces abnormal tau hyperphosphorylation.[¹] In short, the proposed loop is: P021 → more BDNF → less GSK-3β → less tau pathology, plus a direct boost to neurogenesis and synaptic plasticity.

Preclinical evidence. According to PubMed: - In a triple-transgenic (3xTg-AD) mouse model of Alzheimer's disease, 12 months of oral P021 (in diet) significantly reduced abnormal tau hyperphosphorylation, produced a modest reduction in soluble amyloid-beta (with a trend toward reduced plaque load), and rescued deficits in cognition, neurogenesis, and synaptic plasticity — with evidence the effect was BDNF-mediated via reduced GSK-3β.[²] - In aged (22–24-month) Fisher rats, chronic oral P021 reduced age-related decline in learning and memory, reversed the deficit in neurogenesis, increased BDNF, and restored synaptic markers in cortex and hippocampus.[³] - Given before overt pathology developed in 3xTg-AD mice (from 3 to 21 months of age), P021 prevented dendritic and synaptic deficits and cognitive impairment — a "prevention" design.[⁴] - ⚠️ A mixed/negative result. In a 2024 study by an independent group (University of Bologna) in a model of CDKL5 deficiency disorder, P021 rescued neuronal proliferation, survival, and maturation *in vitro* — but chronic *in-vivo* treatment of Cdkl5-knockout mice failed to increase BDNF and did not improve the neuroanatomical defects, with only limited behavioral benefit.[⁵] This is the first published P021 result that is not uniformly positive, and it is a concrete illustration of the translation gap the callouts above describe. - Imaging. A 2026 diffusion-MRI study led by the Medical University of South Carolina reported that diffusion-kurtosis imaging could detect brain microstructural changes in 3xTg-AD mice given early P021 treatment.[⁶] - Origin and design. The compound was first reported in 2010 (then called "P21") as one of a series of adamantane-incorporating neurotrophic peptides that improved learning and memory and promoted neurogenesis and synaptic plasticity in mice.[⁷] A 2015 rat study is the primary source documenting that P021 is blood-brain-barrier-permeable and did not induce a detectable immune reaction, alongside a reduction in elevated CSF tau in aged rats.[⁸]

Evidence quality. The P021 literature is mechanistically detailed but entirely preclinical, and it originated with, and is still largely led by, a single research group — the Iqbal lab at the New York State Institute for Basic Research in Developmental Disabilities. A small number of independent groups have now published on it, including the University of Bologna (CDKL5, 2024)[⁵] and the Medical University of South Carolina (diffusion MRI, 2026)[⁶] — and notably the independent in-vivo result was mixed to negative.[⁵] No human trials exist. Neuroprotective compounds have a long history of promising animal data that does not replicate in people, so P021 should be regarded as an interesting research candidate, not an established cognitive therapy.[⁹]

Regulatory status (US). P021 is not FDA-approved and is not DEA-scheduled. It is available only as a research-supply peptide outside the FDA-recognized supply chain. An early-stage biotech (Phanes Biotech Inc, Malvern, PA) lists P021 as a preclinical development candidate;[⁵] no human trials have begun, and no clinical trial for P021 is registered or published.

Regulatory status (sport — WADA). P021 is not specifically named on the WADA Prohibited List. As a non-approved research peptide it is best treated as captured under S0 (non-approved substances), prohibited at all times. Verify current status via the WADA Prohibited List and your National Anti-Doping Organization.

Common research interests. Cognitive aging, Alzheimer's-type pathology, neurogenesis, and synaptic support. All are extrapolated from animal studies and are not established human uses.

Reported side effects

Commonly reported

Unknown human tolerability — no human has been studied
Neurotrophic signaling effects — promoting neurogenesis and neurotrophic signaling has unknown long-term consequences in humans
Research-supply purity — variable quality of non-pharmaceutical material is a general risk

Contraindications and warnings

Pregnancy and lactation — no data; default to contraindicated

Pediatric use — no data; should not be used in researchers under 18

Active malignancy — caution; effects of enhanced neurotrophic/growth signaling in the cancer context are uncharacterized

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; available only as research-supply material outside the FDA-recognized supply chain. Not DEA-scheduled.

Regulatory note (sport): Not specifically named on the WADA Prohibited List, but best treated as S0 (non-approved substances), prohibited at all times. Verify with your anti-doping organization.

Key terms

Ciliary neurotrophic factor (CNTF): A natural protein that supports the survival and growth of neurons. P021 is a small peptide copied from its most active region.
Neurogenesis: The birth of new neurons, which continues in certain brain regions in adults. P021 is studied for increasing it.
BDNF (brain-derived neurotrophic factor): A protein that supports neuron growth and learning. P021 is reported to raise BDNF, which is part of its proposed mechanism.
Tau hyperphosphorylation: Excess chemical tagging of the tau protein, which drives the tangles seen in Alzheimer's disease. P021 reduced this in mouse models.
Blood-brain barrier: The filter that protects the brain and blocks most large molecules. P021 was chemically modified to cross it, unlike the full CNTF protein.

Sources

Related entries

Cerebrolysin — same mechanism class
Oxytocin — same mechanism class
PE-22-28 — same mechanism class
Selank — same mechanism class
Semax — same mechanism class
Glutathione — shared research area